These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 31954488)

  • 1. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Gut Microbiome and Hepatocellular Carcinoma.
    Akkız H
    J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
    Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
    BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
    Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
    Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiome and liver cancer: mechanisms and clinical translation.
    Yu LX; Schwabe RF
    Nat Rev Gastroenterol Hepatol; 2017 Sep; 14(9):527-539. PubMed ID: 28676707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma.
    Thilakarathna WPDW; Rupasinghe HPV; Ridgway ND
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiota, NASH, HCC and the potential role of probiotics.
    Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
    Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Cancer and Gut Microbiome: Time to Untie Gordian's Knot.
    Aygün C; Tözün N
    J Gastrointest Cancer; 2021 Dec; 52(4):1309-1313. PubMed ID: 34750696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
    Ghoshal UC; Goel A; Quigley EMM
    Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
    Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
    Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.